发明名称 |
Antigen specific multi epitope vaccines |
摘要 |
The present invention relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The peptide vaccines of the invention are characterized by having multiple MHC class I and class II epitopes which are highly abundant in the population. Therefore, these vaccines are likely to induce a strong, comprehensive immune response against the target proteins in the majority of the vaccinated population, and thereby induce an immune reaction against tumors expressing such target proteins. Specifically, the invention relates to peptide vaccines composed of the signal peptide domain of Mucin (MUC1), BAGE-1 or ARMET, and their use for the treatment of cancers which express Mucin (MUC1), BAGE-1 or ARMET. |
申请公布号 |
US9487574(B2) |
申请公布日期 |
2016.11.08 |
申请号 |
US200712442495 |
申请日期 |
2007.09.23 |
申请人 |
VAXIL BIOTHERAPEUTICS LTD. |
发明人 |
Carmon Lior |
分类号 |
A61K39/00;C07K14/74;C07K14/47 |
主分类号 |
A61K39/00 |
代理机构 |
Roberts Mlotkowsi Safran Cole & Calderon P.C |
代理人 |
Hopkins Susanne M.;Roberts Mlotkowsi Safran Cole & Calderon P.C |
主权项 |
1. A peptide vaccine, comprising:
an isolated signal peptide domain of MUC I consisting of an amino acid sequence MTPGT QSPFF LLLLL TVLTV V (SEQ ID NO. 10); and a pharmaceutically acceptable carrier or diluent. |
地址 |
Rehovot IL |